A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
Price : $35 *
At a glance
- Drugs Duligotuzumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Genentech
- 04 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.
- 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2018.